

**Implementation of Pathogen-reduced Platelet
 Additive Solution (PAS) Single Donor Platelets**
Detroit Medical Center University Laboratories
Blood Banks

The Detroit Medical Center University Laboratories will be implementing Pathogen-reduced PAS single donor platelets effective immediately. PAS single donor platelets will be processed using the INTERCEPT Blood System for Platelets Pathogen Reduction System. This pathogen reduction system uses amotosalen, a psoralen derivative, and UVA to irreversibly cross-link nucleic acids blocking the replication of many pathogens and white cells. The use of these products will enable us to:

- Reduce the risk of bacterial contamination and associated sepsis in patients
- Comply with the FDA's guidance on minimizing bacterial contamination
- Reduce risk of transfusion transmitted infection due to viruses and parasites
 - Platelets that have been INTERCEPT treated do not require additional CMV serology
- Reduce risk of transfusion-associated graft-versus-host disease (TA-GVHD) due to T-cells
 - Platelets that have been INTERCEPT treated do not need to be irradiated

Technical/Scientific Information: **Ordering Information and specimen acceptability will not be affected by this change. Continue to order irradiation for patients requiring Irradiated blood products.**

Psoralen Treated Platelet Administration

- Platelet dosing and volume of the new psoralen-treated platelets is the same as conventional platelet products.
- Pre-medication and administration time for psoralen-treated platelets are the same as conventional platelet products.
- Patients may receive both conventional platelets and psoralen treated platelets to fill their requirements.
- Psoralen treated platelets can be hung in the same line as conventional platelets provided the tubing has not expired.

Psoralen Treated Platelet Bag Appearance

- The psoralen treated platelet bags are 2.8 inches longer than conventional platelet bags.
- INTERCEPT Blood System for Platelets is the brand name of the psoralen treatment process and is embossed across the top of the bag.
- Both conventional and psoralen treated platelets are leukoreduced during the apheresis collection process.



Psoralen treated platelets may be used as an alternative to Irradiated Platelets

- Platelets that have been psoralen treated do not require irradiation. Both the FDA and the AABB (Standard 5.19.3.1 for prevention of TA-GVHD) consider the FDA approved INTERCEPT blood system treatment process an alternative to irradiation.
- There will be **NO** RadSure sticker or any other indicator that the platelet has been irradiated on the platelet product. No irradiation will be performed
- The psoralen treated platelets will have a tie tag attached to the unit indicating that psoralen treatment is an alternative to irradiation for the prevention of TA-GVHD.

Technical inquiries:

- DMCUL Blood Bank Laboratory, (313) 745-8565
- Tammon Nash, MD, Medical Director, (313) 993-0561
- Lisah Cane, DMCUL Blood Bank Manager, (313) 745-8380